Mackenzie Financial Corp Sells 73,348 Shares of Humana Inc. (NYSE:HUM)

Mackenzie Financial Corp trimmed its stake in Humana Inc. (NYSE:HUM) by 66.2% during the second quarter, HoldingsChannel.com reports. The fund owned 37,463 shares of the insurance provider’s stock after selling 73,348 shares during the quarter. Mackenzie Financial Corp’s holdings in Humana were worth $13,998,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. increased its position in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares in the last quarter. Hantz Financial Services Inc. acquired a new stake in shares of Humana during the second quarter worth approximately $35,000. Family Firm Inc. bought a new position in shares of Humana in the second quarter valued at approximately $37,000. Hollencrest Capital Management acquired a new position in shares of Humana in the 2nd quarter worth approximately $40,000. Finally, Riverview Trust Co bought a new stake in Humana during the 2nd quarter worth approximately $44,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on HUM. Deutsche Bank Aktiengesellschaft lifted their price objective on Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. TD Cowen upped their price target on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Oppenheimer raised their price objective on shares of Humana from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 target price on shares of Humana in a research report on Friday, September 20th. Finally, Morgan Stanley began coverage on Humana in a research report on Monday, June 24th. They set an “equal weight” rating and a $374.00 target price for the company. Thirteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Humana currently has a consensus rating of “Hold” and an average target price of $398.70.

Humana Trading Up 2.1 %

NYSE:HUM opened at $319.57 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The business’s 50-day simple moving average is $349.94 and its 200-day simple moving average is $344.48. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The stock has a market capitalization of $38.51 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the previous year, the firm posted $8.94 earnings per share. The business’s revenue was up 10.4% on a year-over-year basis. Sell-side analysts expect that Humana Inc. will post 16.01 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.11%. The ex-dividend date is Monday, September 30th. Humana’s payout ratio is presently 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.